ライフサイエンスコーパス: osmotic pump

1 g continuous infusion from an i.p. implanted osmotic pump).

2 was investigated by using a commercial micro-osmotic pump.

3 d with TGFbeta, IL-13, poly(I-C), or TSLP by osmotic pump.

4 ere infused in pregnant C57/BL6 mice by mini-osmotic pump.

5 istration of mecamylamine (50 mg/kg/d) by an osmotic pump.

6 gate the long-term exposure of kisspeptin by osmotic pump.

7 on active EAE in vivo when delivered by s.c. osmotic pump.

8 ,000-fold less than the concentration in the osmotic pump.

9 ys (10 microgram kg(-1). min(-1) SC) with an osmotic pump.

10 ered continuously via an i.p. implanted mini-osmotic pump.

11 GSH was infused intraportally by mini-osmotic pump.

12 ivered subcutaneously into mice using a mini osmotic pump.

13 NG-monomethyl-L-arginine via a subcutaneous osmotic pump.

14 tricular catheters connected to subcutaneous osmotic pumps.

15 eumonectomy and subcutaneous implantation of osmotic pumps.

16 7 days into juvenile male Wistar rats using osmotic pumps.

17 e db/db mice for 28 days via implanted micro-osmotic pumps.

18 ys using the commercially available ALZET(R) osmotic pumps.

19 g daily) for another 3 to 4 weeks using mini-osmotic pumps.

20 ide-damaged rats for 3 or 7 days by means of osmotic pumps.

21 reviously in our laboratory using Alzet mini-osmotic pumps.

22 period via surgically implanted subcutaneous osmotic pumps.

23 s by delivery of exogenous glucagon by micro-osmotic pumps.

24 gentamicin delivered by surgically implanted osmotic pumps.

25 level of spinal cord for 1 or 2 weeks using osmotic pumps (0.5 microl/h).

26 R4 antagonist (AMD3100) was delivered via an osmotic pump 1 day after laser induction.

27 nuously for 14 d using abdominally implanted osmotic pumps (1 mg/kg/d) or i.p. with a single dose (1

28 Mice were given V-PYRRO/NO via osmotic pumps (1.8-5.4 mg/mL, 8 microL/h) 4 to 16 hours

29 ptin over a 1-week period via a subcutaneous osmotic pump (200 micrograms/kg total dose) and (4) comb

30 din-4 (Ex-4) delivered by subcutaneous micro-osmotic pumps 48 hours prior to or 2 hours immediately a

31 IP-9125 oligo was delivered intravenously by osmotic pump alone or in combination with cyclosporine (

32 After chronic administration via a mini-osmotic pump (Alzet), some analogues significantly incre

33 o the portal vein of rats for 24 hours using osmotic pumps and determined whether TNF injection (5 mi

34 eceived steady-state methadone (SSM) through osmotic pumps at 10 or 20 mg/kg/day, and GA was measured

35 T2 mice, we carried out chronic delivery via osmotic pumps attached to bilateral cannulas made of sta

36 duced in rats by administering alinidine via osmotic pumps beginning 1 day after coronary artery liga

37 he entire study period using an Alzert micro-osmotic pump, beginning 3 hours before the induction of

38 he entire study period using an Alzert micro-osmotic pump, beginning 3 hours prior to the induction o

39 ransgenic mice were implanted s.c. with mini-osmotic pumps capable of continuously delivering the SAg

40 fall after being implanted for 30 days with osmotic pumps containing [3H]thymidine.

41 We then implanted osmotic pumps containing buprenorphine or TRV130 (0, 3,

42 Implantation of an osmotic pump delivering 1.5 or 10 microg/h ( approximate

43 When an osmotic pump delivering 10 microg/h of JSM6427 was impla

44 ridine (BrdU) in mouse LE cells after 2-week osmotic pump delivery of BrdU.

45 now challenges these results and shows that osmotic pump delivery of the modified insulin peptide R2

46 A) was chronically infused in the NAcore via osmotic pumps during extinction training.

47 By way of a micro-osmotic pump, each mouse received 50 mM 3CPI in 100 muL

48 into the capillary and the apparent electro-osmotic pumping effect is stopped.

49 after i.c. administration of N5-2OH by Alzet osmotic pumps, either alone or in combination with i.v.

50 Delivery of RO061606 via mini-osmotic pumps enabled the maintenance in vivo in the mou

51 t over 1-2 wk through repeated injections or osmotic pumps enhanced humoral responses, with exponenti

52 thesized AT4 agonist (Norleucine1-AngIV) via osmotic pump facilitated the rate of acquisition to solv

53 mals in group V underwent implantation of an osmotic pump filled with GDNF (100 ng/ml) in the left ea

54 Osmotic pumps filled with bromodeoxyuridine (BrdU) were

55 (SON), delivered with the use of a miniature osmotic pump for 2 weeks in vivo, produced a decrease in

56 lin (10.56 ug/day) or vehicle infusion by an osmotic pump for 3-4 weeks.

57 pproach in nonpregnant mice involving a mini-osmotic pump for continuous 4-day jugular venous infusio

58 ine murine leptin subcutaneous infusion with osmotic pumps for 12-14 days (LEP; 4 mg x kg(-1) x day(-

59 adrenergic receptor antagonist, delivered by osmotic pumps for 21 days.

60 mg/kg per day) was infused via subcutaneous osmotic pumps for 6 days in male hemizygote G6PD mutant

61 s infusion of cocaine (80 mg/kg per day) via osmotic pumps for 7 days into the sensitized rats produc

62 endostatin remains stable and active in mini-osmotic pumps for at least 7 days.

63 n = 7) or saline (n = 7) using subcutaneous osmotic pumps from Day 26 to 160 of gestation.

64 ulate in the subretinal space, exceeding the osmotic pump function of the RPE.

65 ment with BMS-345541 beginning at 20 h after osmotic pump implantation reduced lung NF-kappaB activat

66 rectly to the airways or systemically via an osmotic pump implanted in the peritoneal cavity.

67 Antagonists delivered via osmotic pump in an intratibial severe combined immunodef

68 IL1RN delivered via adenoviral infection or osmotic pumps in inhibiting BLM-induced increases in TNF

69 BMP4 infusion by osmotic pumps increased systolic blood pressure in a tim

70 ion of NG-monomethyl-l -arginine (NGMMA) via osmotic pumps increases the tumor-specific CTL response

71 ical levels of BNP in mice by intravenous or osmotic pump induced significant scratching.

72 Mini-osmotic pump infusion of K201 prevented deleterious remo

73 model of Alzheimer's disease was created by osmotic pump infusion of sub-pathological dose of Abeta

74 ion, and biomechanics were assessed under IV osmotic pump infusions of apelin-13 (0.25 mug/kg/min) or

75 recombinant endostatin administered i.p. by osmotic pump inhibited basic fibroblast growth factor-in

76 inistration was via subcutaneously implanted osmotic pump (initial dose 2.0 mg/kg/day, free base).

77 Ang II or vehicle was infused by osmotic pumps into apoE-KO mice.

78 Third, we implanted osmotic pumps into SCID xenotransplanted mice that deliv

79 ha was delivered subcutaneously using a mini-osmotic pump, it enhanced short-term neutrophil recovery

80 Administration of ASO-9 to rats by osmotic pumps led to an aversion (-61%, P < 0.02) to eth

81 However, administration of LPS over 24 h by osmotic pump (LPS pump) implanted into the peritoneum re

82 ndostatin administered continuously via mini-osmotic pump maintains systemic concentrations of 200-30

83 An intravenous 7-d infusion by osmotic pump of 2.5, 5, 10, or 20 mg/kg BIMO extended ki

84 particularly helpful as the roles of similar osmotic pumps of microcirculation are examined in other

85 0.9% normal saline), via a subcutaneous mini-osmotic pump or single injection (LEP, 300 mug/kg and AM

86 on (1.5 mg kg-1 h-1) by means of a miniature osmotic pump, or identical volume of vehicle (n=24), and

87 fferent ways: centrally, via implantation of osmotic pumps, or systemically by intraperitoneal inject

88 tricular catheters connected to subcutaneous osmotic pumps over 14 days.

89 Intracranial delivery of OS2966 through osmotic pumps over 28 days increased tumor cell apoptosi

90 ic caffeine doses were administered via mini-osmotic pumps over 7 days at 0, 42, 85 and 125 mg kg-1 d

91 UK-189), delivered over a 1 month period via osmotic pump, prevents heat stress-induced liver injury

92 formulation to deliver methylphenidate by an osmotic pump process based on OROS (ALZA Corp, Mountain

93 Before challenge, mice were implanted with osmotic pumps releasing AMD3465 at 5 microg/hour (6 mg/k

94 ministration of nicotine at 2 mg/kg/d via an osmotic pump resulted in a nearly complete saturation of

95 xt, we performed systemic treatment using an osmotic pump that allowed us to deliver different concen

96 of experiments, chickens were implanted with osmotic pumps that administrated the pan-caspase inhibit

97 cement of ventricular catheters connected to osmotic pumps that delivered a continuous infusion of pa

98 a, nonpregnant pigs were implanted with mini-osmotic pumps that delivered CSP to uterine horns.

99 eversible, three monkeys were implanted with osmotic pumps that delivered raclopride for 30 days. We

100 ronic inflammation, mice were implanted with osmotic pumps that delivered tumor necrosis factor-alpha

101 ity was systemically inhibited with apocynin osmotic pumps throughout hypoxia/reoxygenation.

102 ed therapies include a miniature implantable osmotic pump to give continuous delivery of a glucagon-l

103 odium nitroprusside (SNP) was placed in mini-osmotic pumps to deliver 10 micrograms/kg per minute.

104 when administered to the murine brain via an osmotic pump: tPA activity increases along the CA2-CA3 r

105 infusion of low doses of peptide by means of osmotic pumps transforms mature T cells into CD4+25+ sup

106 ats (600 micrograms.kg-1.h-1 by subcutaneous osmotic pump, up to 7 days), (3) sham-operated rats give

107 An osmotic pump was used to deliver IgG across the sclera o

108 Continuous infusion of LPS through mini-osmotic pumps was also associated with increased GSIS.

109 Using a micro-osmotic pump, we directly infused the ASO into a lateral

110 Using miniature osmotic pumps, we now demonstrate that continuous infusi

111 On day 7, miniature osmotic pumps were implanted into the subcutis to contin

112 campal formation would reduce seizures, mini-osmotic pumps were used to continually and focally deliv

113 e manner with purified human HGF provided by osmotic pumps, wherein MetMAb treatment significantly in

114 heart grafts were treated i.v. with a 7-day osmotic pump with 20 mg/kg 17359 alone or in combination

115 Systemic administration of pazopanib by osmotic pump with or without 10 mg/mL drops tid also fai

116 otensin II by using subcutaneously implanted osmotic pumps, with an additional control mouse used for